23 February 2024 in Advanced Materials
Engineered biomaterial scaffolds are becoming more prominent in research laboratories to study drug efficacy for oncological applications in vitro, but do they have a place in pharmaceutical drug screening pipelines? The low efficacy of cancer drugs in phase II/III clinical trials suggests that there are critical mechanisms not properly accounted for in the pre‐clinical evaluation of drug candidates. Immune cells associated with the tumor may account for some of these failures given recent successes with cancer immunotherapies; however, there are few representative platforms to study immune cells in the context of cancer as traditional 2D culture is typically monocultures and humanized animal models have a weakened immune composition. Biomaterials that replicate tumor microenvironmental cues may provide a more relevant model with greater in vitro complexity. In this review, the authors explore the pertinent microenvironmental cues that drive tumor progression in the context of the immune system, discuss how these cues can be incorporated into hydrogel design to culture immune cells, and describe progress toward precision oncological drug screening with engineered tissues.
9 April 2023 in Biomaterials
14 October 2026 in Advanced Healthcare Materials
The role of viscoelasticity in cell invasion within the brain extracellular matrix (ECM) is not well understood in the context of glioblastoma (GBM). We designed biomimetic viscoelastic hyaluronan (HA)‐based hydrogels to understand the effect of viscoelasticity on the invasion of heterogeneous glioblastoma stem cells (GSCs) categorized into subgroups based on molecular profile, as Reactive, Invasive, or Constructive. Hydrogel viscoelasticity was introduced to a hyaluronan‐oxime (HAox) hydrogel to varying degrees through the incorporation of one of methyl cellulose, ECM‐based proteins, tenascin C or collagen IV, or hydrazone chemistry. Each HAox‐derived viscoelastic hydrogel exhibited significantly higher stress relaxation than HAox. We demonstrated that heterogeneous patient‐derived GSC lines respond differently to viscoelasticity, with a strong correlation between greater invasion of Reactive GSCs in faster stress‐relaxing matrices. This work highlights the importance of investigating the behavior of GSCs based on their heterogeneous molecular profiles and contributes to the understanding of the role of viscoelasticity in GSC invasion.